Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.63 |
| ▸ | MMP8 | P22894 | 2/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | ECE1 | P42892 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NMBR | P28336 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067257 | 0.88 | MMP9 (0.59) | MMP9MMP8MMP2TACR1KCNT1 | |
| SCHEMBL7066324 | 0.87 | MMP9 (0.58) | MMP9MMP8MMP2TACR1KCNT1 | |
| SCHEMBL7065632 | 0.85 | MMP9 (0.56) | MMP9MMP8MMP2TACR1KCNT1 | |
| SCHEMBL7064027 | 0.85 | MMP9 (0.56) | MMP9MMP8MMP2TACR1KCNT1 | |
| SCHEMBL7064254 | 0.81 | MMP9 (0.58) | MMP9MMP8MMP2TACR1KCNT1 | |
| SCHEMBL8201153 | 0.81 | MMP9 (0.80) | MMP9MMP8MMP2TACR1ACE | |
| SCHEMBL8201151 | 0.81 | MMP9 (0.80) | MMP9MMP8MMP2TACR1ACE | |
| SCHEMBL8850370 | 0.81 | MMP9 (0.80) | MMP9MMP8MMP2TACR1ACE | |
| SCHEMBL7066023 | 0.80 | MMP9 (0.61) | MMP9MMP8MMP2TACR1ACE | |
| SCHEMBL7062283 | 0.79 | MMP9 (0.60) | MMP9MMP8MMP2TACR1KCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065007-A1 | NK1 receptor antagonists | CRESWELL MARK WALLACE (US) | 2003-04-03 | — | — | US | disclosed |
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | disclosed |
| EP-1140914-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037462-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065007-A1 | NK1 receptor antagonists | HRH1, HRH4, HRH2 | MMP9 4069/4885MMP8 688/4885MMP2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.